While biotech is seeing renewed investor interest after being 'left for dead,' its culture differs from mainstream tech. Instead of chasing unicorn-or-bust 'power law' outcomes, the biotech community often prioritizes more frequent, smaller exits in the low billions, creating a pattern of 'base hits' and serial entrepreneurship.

A massive influx of capital into Chinese biotech, followed by a public market slowdown, left many innovative companies "trapped" without funding. This created a unique opportunity for Western pharma and VCs to license high-quality assets, driving pharma's China deal volume from single digits to nearly 50%.

The strong biotech market performance in 2025 was not a case of a rising tide lifting all boats. Outperformance was concentrated in companies with strong fundamentals and backing from specialist investors, indicating a healthy, discerning market that rewards quality over speculation.

Non-specialist 'tourist investors,' often from the tech sector, are re-entering biotech, attracted by hype around AI and longevity. Their influence is leading to inflated valuations and connecting biotech stock performance to the whims of the tech market. This influx creates risk, as a downturn in tech could disproportionately harm biotech companies funded by this crossover capital.

The biotech landscape in Southeast Asia has strong scientific talent but lacks a mature 'translation ecosystem' (VCs, experienced operators). Founders must take on the dual role of building their company and simultaneously cultivating the surrounding infrastructure, including talent, partnerships, and public trust.

BeiGene's success demonstrates a new model for biotech growth. It started in China and expanded globally, but critically maintains China as a core hub for innovation. This challenges the traditional view that biotech innovation flows primarily from the West and must be built from a US headquarters.

A biotech boom in China, fueled by returning scientists and VC funding, hit a wall when public market access was restricted. This liquidity crunch left many high-quality companies with promising assets undervalued and in need of capital, creating a prime investment window for savvy foreign investors to acquire technology.

Barcelona is an emerging biotech hub due to a specific formula: 1) excellent basic research institutions, 2) top-tier hospitals for clinical trials, 3) an active local early-stage VC community, and 4) a regional culture of entrepreneurship. This combination creates a fertile ground for new ventures to form and thrive.

The prolonged downturn eliminated weaker competition and forced surviving companies to become financially disciplined. This "cleansing moment" means remaining players face a better competitive landscape and operate with leaner cost structures, setting them up for significant upside as the market recovers.